Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
3T Biosciences, founded in 2017 and headquartered in South San Francisco, California, is an innovative immunotherapy company focused on developing transformative therapies for solid tumors and immune-mediated diseases. The company specializes in harnessing the immune system's ability to recognize, target, and destroy cancer cells, with the aim of advancing safer treatments for difficult-to-treat cancers.
Since its inception, 3T Biosciences has made significant strides in the biotechnology sector, having raised a total of $52.25 million in funding. This substantial investment underscores the potential of their groundbreaking approach to cancer treatment and the confidence of investors in their technology.
While there is currently no concrete information available regarding 3T Biosciences' IPO prospects, the company's innovative focus and substantial funding could potentially position it for future growth opportunities. However, it's important to note that any discussions about a potential IPO for 3T Biosciences remain speculative at this time.
Factors that may influence any future IPO decisions for 3T Biosciences could include the progress of their research and development efforts, the outcomes of clinical trials, and overall market conditions in the biotechnology sector. As with any potential investment opportunity, it's crucial for investors to conduct thorough research and consider the risks associated with investing in early-stage biotech companies.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While 3T Biosciences' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative biotech space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotechnology sector, like 3T Biosciences, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of cutting-edge companies in the healthcare industry before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
